ESR1 and breast cancer: In the transcriptome analysis of patients with ER-positive BC receiving tamoxifen, SETD1A and SOX2 transcriptional levels were significantly increased in tamoxifen-resistant patients than in the tamoxifen-sensitive patients (Figure 7J).